Business Context and Reporting Period
Company: Senseonics Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2016
Event: Entry into an Amended and Restated Loan and Security Agreement and termination of a prior loan agreement.
Key Financial Metrics and Debt Structure
Debt Facility: The Company entered into a new credit facility with Oxford Finance LLC and Silicon Valley Bank allowing for potential borrowings up to $30.0 million in four tranches.
- Tranche 1 (Funded): $15.0 million issued on the Closing Date.
- Tranche 2 (Conditional): Up to $5.0 million available by December 31, 2016, contingent on positive U.S. pivotal trial data for Eversense and filing of a PMA application.
- Tranche 3 (Conditional): Up to $5.0 million available by April 30, 2017, contingent on borrowing Tranche 2 and completing the first commercial sale of the second-generation transmitter in the EU.
- Tranche 4 (Conditional): Up to $5.0 million available by December 31, 2017, contingent on borrowing Tranches 2 and 3, receiving FDA PMA approval, and achieving trailing six-month revenue of at least $4.0 million.
Interest and Fees:
- Interest Rate: Floating rate of 6.31% plus the greater of 90-day LIBOR or 0.64%, with a minimum floor of 6.95%.
- Final Payment: 9.00% of aggregate principal balances due at maturity or prepayment.
- Non-Utilization Fee: 2.00% of undrawn amounts if Tranche 3 or 4 conditions are met but not borrowed.
- Prepayment Fees: 3.00% (Year 1), 2.00% (Year 2), or 1.00% (Year 3+).
Repayment of Prior Debt: Approximately $11 million of Tranche 1 proceeds were used to repay the outstanding balance of the Original Loan Agreement (dated July 31, 2014), including a $1 million final payment fee. The prepayment fee on the original loan was waived.
Equity Issuance: The Company issued warrants to purchase 116,581 shares of common stock at an exercise price of $3.86 per share. Additional warrants (3.00% of funded amounts) may be issued upon borrowing subsequent tranches.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's debt obligations. The Original Loan Agreement with Oxford was terminated and replaced by the new Amended and Restated Loan and Security Agreement. This new agreement increases the potential borrowing capacity from the prior outstanding balance to a maximum of $30.0 million, subject to specific clinical and commercial milestones.
Guidance, Outlook, Risks, and Contingencies
Collateral and Covenants: The Term Loans are collateralized by all of Senseonics' assets except intellectual property, which is subject to a negative pledge. The agreement includes restrictive covenants limiting additional indebtedness, liens, mergers, changes of control, acquisitions, new business lines, investments, dividends, and asset transfers.
Events of Default: Includes bankruptcy, failure to make payments, material impairment of security interest, material adverse change, default under other agreements, judgments, revocation of government approvals, and covenant violations. Upon default, interest rates increase by 5.00% and amounts may be declared immediately due.
Unregistered Securities: The warrants were issued under Regulation D and Section 4(a)(2) exemptions and are not registered under the Securities Act of 1933.
Financial Reporting: The filing text does not provide specific revenue, profit, cash flow, or margin figures for the period; it focuses exclusively on the debt restructuring transaction.
Important Facts for Investor Verification
- Verify the status of the U.S. pivotal trial for Eversense to assess the likelihood of accessing the $5.0 million Tranche 2 funding.
- Confirm the timeline for FDA PMA approval and the first commercial sale in the EU to evaluate access to Tranches 3 and 4.
- Review the impact of the 9.00% final payment fee and the minimum 6.95% interest floor on future cash flow requirements.
- Monitor the dilution impact of the initial 116,581 warrants and potential additional warrants tied to future tranches.
- Assess the restrictive covenants regarding dividends and additional indebtedness against the Company's strategic plans.